SCHEMBL524745

SCHEMBL524745

O=CC(Br)c1ccc2cc(Br)ccc2c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 3/20 0.43
ALDH1A1 P00352 2/20 0.41
MAPT P10636 2/20 0.41
KDM4E B2RXH2 1/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
ERN1 O75460 2/20 0.39
NCEH1 Q6PIU2 1/20 0.34
BACE1 P56817 1/20 0.32
LMNA P02545 3/20 0.32
PKM P14618 1/20 0.32
DHODH Q02127 1/20 0.32
L3MBTL1 Q9Y468 2/20 0.32
CYP11B1 P15538 1/20 0.32
CYP11B2 P19099 1/20 0.32
NPC1 O15118 1/20 0.31
RAB9A P51151 1/20 0.31
ATM Q13315 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
TDP1 Q9NUW8 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1701106 0.82 UGT2B7 (0.47) CYP2A6MEN1KMT2AATM
SCHEMBL20299625 0.82 UGT2B7 (0.47) CYP2A6MEN1KMT2AATM
SCHEMBL2479755 0.79 CYP2A6 (0.42) CYP2A6ALDH1A1MAPTKDM4EMEN1
SCHEMBL22590138 0.79 CYP2A6 (0.40) CYP2A6ALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL321965 0.79 CYP2A6 (0.40) CYP2A6ALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL27865081 0.77 CYP2A6 (0.39) CYP2A6ALDH1A1MAPTKDM4EMEN1
SCHEMBL5504556 0.77 AKR1C3 (0.53) CYP2A6MAPTKDM4ELMNAL3MBTL1
SCHEMBL12492235 0.76 CYP1A2 (0.41) ERN1BACE1
SCHEMBL540882 0.76 ALDH1A1 (0.47) ALDH1A1
SCHEMBL21495049 0.76 ALDH1A1 (0.47) ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2797913-A1 QUINAZOLINONE DERIVATIVES AS HCV INHIBITORS Janssen R&D Ireland (IE) 2014-11-05 EP disclosed
EP-2640719-A2 ANTIVIRAL COMPOUNDS Gilead Sciences, Inc. (US) 2013-09-25 EP disclosed
WO-2013098320-A1 QUINAZOLINONE DERIVATIVES AS HCV INHIBITORS JANSSEN R&D IRELAND (IE) 2013-07-04 WO disclosed
EP-2598498-A1 HETERO-BICYCLIC DERIVATIVES AS HCV INHIBITORS Janssen R&D Ireland (IE) 2013-06-05 EP disclosed
WO-2012123298-A1 ANTIVIRAL COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2012-09-20 WO disclosed
EP-2499127-A1 HEPATITIS C VIRUS INHIBITORS Bristol-Myers Squibb Company (US) 2012-09-19 EP disclosed
EP-2499115-A1 HEPATITIS C VIRUS INHIBITORS Bristol-Myers Squibb Company (US) 2012-09-19 EP disclosed
EP-2496572-A1 BENZIMIDAZOLE-IMIDAZOLE DERIVATIVES Janssen R&D Ireland (IE) 2012-09-12 EP disclosed
WO-2012068234-A2 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. (US) 2012-05-24 WO disclosed
WO-2012013643-A1 HETERO-BICYCLIC DERIVATIVES AS HCV INHIBITORS TIBOTEC PHARMACEUTICALS (IE) 2012-02-02 WO disclosed
WO-2011091446-A1 CHEMICAL COMPOUNDS GLAXOSMITHKLINE LLC (US) 2011-07-28 WO disclosed
WO-2011059887-A1 HEPATITIS C VIRUS INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2011-05-19 WO disclosed
WO-2011059850-A1 HEPATITIS C VIRUS INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2011-05-19 WO disclosed
WO-2011054834-A1 BENZIMIDAZOLE-IMIDAZOLE DERIVATIVES TIBOTEC PHARMACEUTICALS (IE) 2011-05-12 WO disclosed